HomeAbout

TL;DR CNBC


CDC advisors recommend mpox vaccine for at-risk adults in future outbreaks - TL;DR CNBC

CDC advisors recommend mpox vaccine for at-risk adults in future outbreaks

Publishing timestamp: 2023-02-22 14:20:42


Summary

The CDC's independent advisors have recommended Jynneos vaccine, made by Danish company Bavarian Nordic, for adults at risk of mpox in potential future outbreaks. The vaccine has been used widely in the US in response to a sudden outbreak last year, which has caused more than 30000 cases and 32 deaths. The CDC advisors will meet again in June to discuss using Jynneos vaccine for kids at risk of mpox in future outbreaks. Studies have found two doses of Jynneos vaccine to be at least 66% effective in preventing mpox, and serious side effects from the vaccine were rare among adults.


Sentiment: NEUTRAL

Tickers: BAVA-DKBVNRY

Keywords: health care industrybusiness newsbusinesspoliticsbiotechnologycoronavirusepidemicsbavarian nordic a/sbiotech and pharmaceuticalsdisease outbreaksbreaking news: businesspandemicsu.s. economy

Source: https://www.cnbc.com/2023/02/22/mpox-cdc-advisors-recommend-vaccine-for-at-risk-adults-in-future-outbreaks.html


Developed by Leo Phan